Macular telangiectasia (sometimes called idiopathic juxtafoveal telangiectasis or MacTel) is a disease that affects the macula. That's the part of your eye that allows you to see things directly in ...

New PRMRP designation creates dedicated pathway for HHT-focused research through the Department of Defense’s Congressionally Directed Medical Research Programs This is a defining moment…This federal ...

Affecting the nervous system, immune system and other body organs, ataxia telangiectasia is characterized with uncoordinated movements of the individual suffering from this disorder. The secondary ...

Macular telangiectasia (MacTel) type 2 is a disease that affects your macula, which is in your eye. It's an area in the center of your retina – the light-sensitive tissue at the back of your eye.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Macular telangiectasia type 2 is a progressive and ...

The eye condition, which can induce the loss of central vision, could see effective treatment options pending FDA approval. Macular telangiectasia (MacTel) has long gone without a consensus treatment ...

Hereditary hemorrhagic telangiectasia, or Osler–Weber–Rendu syndrome, is an autosomal dominant vascular disorder that affects multiple systems. It is characterized by skin and mucosal telangiectasias ...

Ataxia-telangiectasia (A-T) is a rare human genetic disorder that is characterized by cancer predisposition, neurodegeneration, immunodeficiency, radiosensitivity, chromosomal instability and ...

IMMUNOLOGIC abnormalities, including hypogammaglobulinemia, abnormalities of gamma 1 A globulin, poor homograft rejection and structural abnormalities of the thymus gland, have recently been reported ...

IntraBio Inc., a global biopharmaceutical company focused on developing and commercializing therapies for neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...

Supported by phase 3 trial data showing significant SARA score improvements, levacetylleucine is on track to potentially become the first approved therapy for A-T.

This page lists all known medications that could potentially lead to 'Telangiectasia' as a side effect. It's important to note that mild side effects are quite common with medications. The ...